Bastion Therapeutics utilizes its proprietary GRIT™ platform to engineer regulatory T cells that restore balance in dysregulated immune systems, specifically targeting inflammatory disorders. The startup aims to develop curative therapies for over 600 million people worldwide suffering from these conditions.
Funding
Funding not disclosed
Founders
Product
Problem
Many inflammatory disorders arise from an imbalance in the immune system, where regulatory T cells (Tregs) fail to adequately control inflammatory responses. This dysregulation can lead to chronic inflammation and tissue damage, affecting over 600 million people worldwide. Current treatments often manage symptoms but do not address the underlying immune imbalance.
Solution
Bastion Therapeutics is developing engineered Treg cell therapies designed to restore immune balance and provide curative potential for inflammatory disorders. Their GRIT™ (Gene-edited Regulatory Immune cells Therapy) platform enables the engineering of Tregs to enhance their suppressive function and target them to specific sites of inflammation. By re-establishing immune homeostasis, Bastion aims to resolve the root cause of inflammatory diseases, offering a more durable and effective therapeutic approach compared to existing treatments. The company is advancing its early programs towards clinical trials.
Target Audience
The primary target audience includes patients suffering from inflammatory disorders, as well as physicians and healthcare providers specializing in immunology and cell therapy.
Features
- GRIT™ platform for engineering regulatory T cells with enhanced suppressive function.
- Disease-specific targeting of Tregs to sites of inflammation.
- Gene editing technology to modify Treg function and specificity.
- Development of cell therapies with curative potential for inflammatory disorders.